I
Ira Pastan
Researcher at Laboratory of Molecular Biology
Publications - 1304
Citations - 113191
Ira Pastan is an academic researcher from Laboratory of Molecular Biology. The author has contributed to research in topics: Immunotoxin & Pseudomonas exotoxin. The author has an hindex of 160, co-authored 1286 publications receiving 110069 citations. Previous affiliations of Ira Pastan include Heidelberg University & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Engineered Anti-GPC3 Immunotoxin, HN3-ABD-T20, Produces Regression in Mouse Liver Cancer Xenografts Through Prolonged Serum Retention
Bryan D Fleming,Daniel J. Urban,Matthew D. Hall,Thomas Longerich,Tim F. Greten,Ira Pastan,Mitchell Ho +6 more
TL;DR: Treatment of hepatocellular carcinomas using glypican‐3 (GPC3)‐targeting human nanobody (HN3) immunotoxins causes potent tumor regression by blocking protein synthesis and down‐regulating the Wnt signaling pathway.
Journal ArticleDOI
Recombinant Toxins: New Therapeutic Agents for Cancer
Journal ArticleDOI
The purification and properties of a thyroid-stimulating factor isolated from Clostridium perfringens.
TL;DR: Cultures of Clostridium perfringens produce a factor that stimulates the thyroid that has been purified 300-fold by fractionation of the growth medium with ammonium sulfate, filtration on Sephadex G-100, and chromatography on diethylaminoethyl cellulose.
Journal ArticleDOI
Increased affinity and stability of an anti-HIV-1 envelope immunotoxin by structure-based mutagenesis.
Louise McHugh,Stella Hu,Byungkook Lee,Kenneth Santora,Paul E. Kennedy,Edward A. Berger,Ira Pastan,Dean H. Hamer +7 more
TL;DR: Three-dimensional structural information and phage selection data are used to design site-directed mutants that may increase the utility of immunotoxins for reducing or eradicating persistent HIV-1 infection in humans.
Journal ArticleDOI
Construction of an immunotoxin, HN3-mPE24, targeting glypican-3 for liver cancer therapy
TL;DR: The HN3-mPE24 immunotoxin caused liver tumor regressions and extended survival with no significant side effects in mice, and is a promising candidate for the treatment of liver cancer that may be readily translated to humans.